This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Cardiovascular System  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Bernd Jilma, MD; Florian M. Kovar, MD; Gregor Hron, MD; Georg Endler, MD; Claudia L. Marsik, MD; Sabine Eichinger, MD; Paul A. Kyrle, MD

Arch Intern Med. 2006;166:1655-1659.

Background  The single nucleotide polymorphism (SNP) Ser128Arg in the E-selectin gene is overrepresented in certain patient populations with atherosclerosis or restenosis. As this SNP enhances tissue factor–triggered coagulation in humans during systemic inflammation, we hypothesized that it may also predispose for the development of recurrent venous thromboembolism (VTE).

Methods  A total of 585 patients were prospectively observed after first VTE for recurrent, objectively documented, symptomatic VTE. Patients with secondary VTE, homozygous factor V Leiden, natural inhibitor deficiencies, lupus anticoagulant, or long-term anticoagulation therapy were excluded. The S128R SNP was genotyped by mutagenically separated polymerase chain reaction.

Results  A total of 102 patients (17%) were heterozygous, and 11 were homozygous (2%) for the Ser128Arg mutation. Ninety patients (15%) had recurrent VTE during follow-up. Homozygosity for the Ser128Arg SNP increased the cumulative likelihood, particularly for early recurrent VTE (log rank test, P<.05) and was an independent predictor of recurrent VTE (hazard ratio [HR], 4.1; 95% confidence interval [CI], 1.5-11.4) in a multivariate Cox regression model. In contrast, heterozygosity for the polymorphism was associated with an unaltered HR (HR, 1.1; 95% CI, 0.6-1.9) for recurrent VTE.

Conclusions  Homozygosity for the S128R E-selectin allele appears to increase the risk for recurrent VTE several fold. If these findings are confirmed, this may represent a novel risk factor for recurrent VTE. These results also expand our knowledge on the association of this SNP with thrombotic disorders.

Author Affiliations: Departments of Clinical Pharmacology (Drs Jilma, Kovar, and Marsik) and Internal Medicine (Drs Hron, Eichinger, and Kyrle), and Clinical Institute for Medical and Chemical Laboratory Diagnostics (Drs Endler and Marsik), Medical University of Vienna, Vienna, Austria.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?